Clinical Trials Directory

Trials / Completed

CompletedNCT03357276

Mix Vaccine for Metastatic Colorectal Cancer

Safety and Efficacy Study of Mix Vaccine in Colorectal Cancer Patient

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Fuda Cancer Hospital, Guangzhou · Academic / Other
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is the safety and efficacy of mix vaccine to small metastases of colorectal cancer.

Detailed description

By enrolling patients with small metastases of colorectal cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions

Interventions

TypeNameDescription
BIOLOGICALMix vaccineEach treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle

Timeline

Start date
2017-11-30
Primary completion
2018-11-30
Completion
2019-08-30
First posted
2017-11-29
Last updated
2019-09-12

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03357276. Inclusion in this directory is not an endorsement.

Mix Vaccine for Metastatic Colorectal Cancer (NCT03357276) · Clinical Trials Directory